Grazoprevir/elbasvir combo shows high cure rate for patients with chronic HCV

Sunday, April 26, 2015 - 21:20 in Health & Medicine

Once-daily oral grazoprevir/elbasvir combination therapy, taken without interferon or ribavirin for 12 weeks, demonstrated high sustained virologic response rates for treatment-naive patients with cirrhotic or non-cirrhotic chronic hepatitis C virus (HCV) genotype 1, 4, or 6. These findings suggest that once-daily oral grazoprevir/elbasvir represents a new therapeutic option for chronic HCV infection.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net